Chi Biomedical Ltd., Limassol, Cyprus.
Cell Transplant. 2020 Jan-Dec;29:963689720954434. doi: 10.1177/0963689720954434.
Cardiovascular regeneration aims to renew damaged or necrotic tissue and to enhance cardiac functional performance. Despite the hope arisen from the introduction and use of stem cells (SCs) as a novel cardiac regenerative approach, to-this-date, clinical trial findings are still ambivalent despite preclinical successes. Concurrently, noninvasive magnetic resonance imaging (MRI) advances have been based on nanotechnological breakthroughs that have (a) allowed fluorinated nanoparticles and ultrasmall iron oxide single-cell labeling, (b) explored imaging detection sensitivity limits (for preclinical/low-field clinical settings), and (c) accomplished cellular tracking . Nevertheless, outcomes have been far from ideal. Herein, the recently developed preclinical and clinical H and F MRI approaches for direct cardiac SC labeling techniques intended for cellular implantation and their potential for tracking these cells in health and infarcted states are summarized. To this extent, the potential preclinical and clinical values of F MRI and tracking of SCs for cardiac regeneration in myocardial infarction are questioned and challenged.
心血管再生旨在更新受损或坏死的组织,并增强心脏的功能表现。尽管引入和使用干细胞 (SCs) 作为一种新的心脏再生方法带来了希望,但迄今为止,尽管临床前取得了成功,临床试验结果仍然存在矛盾。与此同时,非侵入性磁共振成像 (MRI) 的进展基于纳米技术的突破,这些突破 (a) 允许氟化物纳米粒子和超小氧化铁单细胞标记,(b) 探索了成像检测灵敏度极限(用于临床前/低场临床环境),以及 (c) 实现了细胞追踪。然而,结果远非理想。在此,总结了最近开发的用于细胞植入的直接心脏 SC 标记技术的临床前和临床 H 和 F MRI 方法及其在健康和梗死状态下追踪这些细胞的潜力。在这方面,质疑和挑战了 F MRI 的潜在临床前和临床价值以及 SCs 在心肌梗死中的心脏再生追踪。